La vendita allo scoperto per Amylyx Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Amylyx Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Amylyx Pharma (NASDAQ:AMLX) Azioni, Report sulle vendite allo scoperto

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

<p>The earnings results for <strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) for Q3 were made public on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data in hand, it's essential to compare its metrics to those of similar companies, including PubMatic, TechTarget, and National CineMedia.</p>
<ul>
<li>The latest earnings announcement from PubMatic on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's estimate of $-0.02, resulting in a 950.0% increase.</li>
<li>The latest earnings announcement from TechTarget on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's estimate of $0.4, resulting in a 5.0% increase.</li>
<li>The latest earnings report from National CineMedia on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $-0.03, National CineMedia reported an EPS of $-0.04, marking a -33.33% decrease.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
<p>The provided analysis offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Delving into Peer Revenue Comparison: Estimated vs. Announced</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Insights into Clear Channel Outdoor Q3 Earnings

<p>MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) reported quarterly earnings of $0.73 per share which met the analyst consensus estimate.  The company reported quarterly sales of $200.710 million which beat the analyst consensus estimate of $200.406 million by 0.15 percent.  This is a 33.47 percent increase over sales of $150.375 million the same period last year.</p>


Earnings Beats

News

MTSI

MACOM Technology Solns Q4 2024 Adj. EPS $0.73, Inline, Sales $200.710M Beat $200.406M Estimate

Guidance

Turning Point Brands Raised Previous Full-year 2024 Adjusted EBITDA Guidance From $98M-$102M To $101M-$103M, Excluding CDS

THRY

Thryv Holdings See FY24 Adj. EBITDA $33.5M-$34.5M

Thryv Holdings Sees Q4 Adj. EBITDA $9.5M-$10.5M

<p>Seaport Global  analyst Aaron Kessler   downgrades Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from Buy to Neutral.</p>


Downgrades

Analyst Ratings

DUOL

Seaport Global Downgrades Duolingo to Neutral

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) with a Buy and maintains $90 price target.</p>


Price Target

Reiteration

DNLI

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

<p>Anywhere Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.62 billion by 5.46 percent.  This is a 3.09 percent decrease over sales of $1.58 billion the same period last year.</p>


Earnings Misses

HOUS

Anywhere Real Estate Q3 Sales $1.53B Miss $1.62B Estimate

Stock Split

General

TRNR

Interactive Strength Announces 1-For-100 Reverse Split, Effective November 11

<p><strong>2024 Fourth Quarter Financial Outlook</strong></p>
<p>Management provided an outlook for the fourth quarter, the period ending December 31, 2024. Based on current estimates, management expects:</p>
<ul>
<li>$181 million to $191 million in revenue</li>
<li>$1.51 to $1.70 in diluted GAAP EPS</li>
<li>$1.72 to $1.91 in diluted non-GAAP EPS</li>
</ul>


NVMI

Nova Expects Q4 Revenue Of $181M-$191M Vs $171.84M Est, Adj EPS Of $1.72-$1.91 Vs $1.68 Est

<p>Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly losses of $(2.65) per share which missed the analyst consensus estimate of $(0.95) by 178.95 percent.  The company reported quarterly sales of $179.852 million which beat the analyst consensus estimate of $179.230 million by 0.35 percent.  This is a 2.16 percent decrease over sales of $183.822 million the same period last year.</p>


Thryv Holdings Q3 2024 GAAP EPS $(2.65) Misses $(0.95) Estimate, Sales $179.852M Beat $179.230M Estimate

<p>Barclays  analyst Lauren Lieberman   downgrades Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowers the price target from $8 to $7.</p>


COTY

Barclays Downgrades Coty to Underweight, Lowers Price Target to $7

<p>Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) affirms FY2024 sales outlook from $875.00 million-883.00 million to $875.00 million-883.00 million.</p>


PRTH

Priority Tech Holdings Affirms FY2024 Sales Guidance from $875.00M-883.00M to $875.00M-883.00M

<p>ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent.  The company reported quarterly sales of $18.464 million which beat the analyst consensus estimate of $18.462 million by 0.01 percent.  This is a 27.40 percent increase over sales of $14.493 million the same period last year.</p>


ADCT

ADC Therapeutics Q3 2024 Adj. EPS $(0.28) Beats $(0.40) Estimate, Sales $18.464M Beat $18.462M Estimate

<p>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) reported quarterly losses of $(2.83) per share which missed the analyst consensus estimate of $(1.19) by 137.82 percent.</p>


AVTX

Avalo Therapeutics Q3 2024 GAAP EPS $(2.83) Misses $(1.19) Estimate, Cash Position Of Approximately $82M With Subsequent Receipt Of Approximately $58M Of Warrant Exercise Proceeds In 4Q 2024, Provides Expected Runway Into At Least 2027

<p>Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.06 by 583.33 percent. This is a 2.5 percent increase over earnings of $0.40 per share from the same period last year.  The company reported quarterly sales of $179.650 million which missed the analyst consensus estimate of $179.865 million by 0.12 percent.  This is a 3.05 percent increase over sales of $174.333 million the same period last year.</p>


CARS

Cars.com Q3 2024 Adj. EPS $0.41 Beats $0.06 Estimate, Sales $179.650M Miss $179.865M Estimate

<p>Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.72 by 20.83 percent. The company reported quarterly sales of $105.617 million which beat &nbsp;the analyst consensus estimate of $100.713 million by 100.00 percent. This is a 100.00 percent decrease over sales of $101.722 million the same period last year.</p>


Turning Point Brands Q3 2024 Adj. EPS $0.87 Beats $0.72 Estimate, Sales $105.617M Beat $100.713M Estimate

ISPC

iSpecimen Reveals Significant Enhancement To Its Searchable Inventory; Unveils Cancer Biospecimen Offering; Orders Anticipated Of Over $9.50M Annually

<p>MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) sees Q4 sales of $149.000 million-154.000 million vs $135.21 million estimate.</p>


MoneyLion Sees Q4 Sales $149.000M-154.000M vs $135.21M Est

<p>MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) raises FY2024 sales outlook from $525.00 million-535.00 million to $536.00 million-541.00 million.</p>


MoneyLion Raises FY2024 Sales Guidance from $525.00M-535.00M to $536.00M-541.00M

Amylyx Pharmaceuticals, Inc. (AMLX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Amylyx Pharmaceuticals, Inc. is poi...

Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility

Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report) ...

Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intra-Cellular Therapies (ITCI – Research Report), Amylyx Pharmac...

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on AMLX stock, giving a Hold rating on October 17. Graig Suvannavej...

Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties

As previously reported, BofA analyst Charlie Yang upgraded Amylyx (AMLX) to Buy from Neutral with a price target of $10, up from $4.20, based on th...

Amylyx upgraded to Buy at BofA on 'underappreciated' PBH opportunity

BofA upgraded Amylyx (AMLX) to Buy from Neutral with a $10 price target Published first on TheFly – the ultimate source for real-time, market-movin...

Amylyx upgraded to Buy from Neutral at BofA

Bank of America Securities analyst Charlie CY Yang maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report) today. The compan...

Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), GlaxoSmithKline (GSK – Research ...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

INGN

INSM

ISRG

ITCI

NMRA

NRGV

VTYX

Press Releases

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Legal

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Comments

Amylyx Pharma

Vendite allo scoperto

Amylyx Pharma (NASDAQ:AMLX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO